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ackground: Limited data are available regarding C1 inhibitor (C1-INH) administration and antieC1-INH
ntibodies.
bjective: To assess the incidence of antibody formation during treatment with pasteurized, nanoﬁltered
lasma-derived C1-INH (pnfC1-INH) in patients with hereditary angioedema with C1-INH deﬁciency
(C1-INH-HAE) and the comparative efﬁcacy of pnfC1-INH in patients with and without antibodies.
Methods: In this multicenter, open-label study, patients with C1-INH-HAE (12 years of age) were given 20
IU/kg of pnfC1-INH per HAE attack that required treatment and followed up for 9 months. Blood samples
were taken at baseline (day of ﬁrst attack) and months 3, 6, and 9 and analyzed for inhibitory antieC1-INH
antibody (iC1-INH-Ab) and noninhibitory antieC1-INH antibodies (niC1-INH-Abs).
Results: The study included 46 patients (69.6% female; mean age, 38.9 years; all white) who received 221
on-site pnfC1-INH infusions; most patients received 6 or fewer infusions. No patient tested positive (titer
1:50) for iC1-INH-Ab at any time during the study. Thirteen patients (28.2%) had detectable niC1-INH-Abs
in 1 or more samples. Nine patients (19.6%) had detectable niC1-INH-Abs at baseline; 3 of these had no
detectable antibodies after baseline. Of 10 patients (21.7%) with 1 or more detectable result for niC1-INH-Abs
after baseline, 6 had detectable niC1-INH-Abs at baseline. Mean times to symptom relief onset and complete
symptom resolution per patient were similar for those with or without antieniC1-INH-Abs.
Conclusion: Administration of pnfC1-INH was not associated with iC1-INH-Ab formation in this population.
Noninhibitory antibodies were detected in some patients but ﬂuctuated during the study independently of
pnfC1-INH administration and appeared to have no effect on pnfC1-INH efﬁcacy.
Trial Registration: clinicaltrials.gov Identiﬁer: NCT01467947.
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Hereditary angioedema (HAE) is a rare autosomal dominant dis-
order. Three forms of HAE have been described, 2 of which are char-
acterized by a deﬁciency of functional C1-INH (C1-INH-HAE). Type I
accounts for approximately 85% of cases and is characterized by
impaired synthesis of C1-INH, resulting in a quantitative decrease of
C1-INHantigenic blood concentrations. Type IIHAE is associatedwith
production of dysfunctional C1-INHbut presentswith normal or high
levels of the protein. A third phenotypic variant, HAEwithnormal C1-
INH(sometimes referred toas type III), is sometimesassociatedwitha
genetic factor XII mutation; however, in most cases, the cause re-
mains unknown.1e4lsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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option in HAE management.3,5,6 The plasma-derived, highly puri-
ﬁed, pasteurized, nanoﬁltered C1-INH concentrate (pnfC1-INH
[Berinert], CSL Behring, King of Prussia, PA) is approved in the
United States for the treatment of acute facial, abdominal, and
laryngeal HAE attacks in adolescents and adults and has been
available since 2009. pnfC1-INH has been available in a pasteurized,
nanoﬁltered formulation in Europe since 2010 andwas preceded by
a pasteurized predecessor version ﬁrst marketed in 1985; it is
currently licensed in the European Union for the treatment of acute
HAE attacks and for short-term prophylaxis in children and adults.
In one study, pnfC1-INH was found to have the highest purity
proﬁle of human plasma-derived C1-INH products.7
Therapeutic proteins may present a risk of inducing an un-
wanted antibody (Ab) response, including the development of Abs
to the protein itself.8e10 Such antidrug Abs can be transiently
expressed and of no clinical consequence (noninhibitory) or may
potentially result in reduced efﬁcacy if they block the activity of the
therapeutic protein (inhibitory or neutralizing). Auto-Abs to
C1-INH (C1-INH-Abs) are a hallmark of acquired C1-INH
deﬁciency11e13 and may alter clinical responsiveness to
exogenous C1-INH administration because of rapid catabolism.14
C1-INH-Abs have been observed in some patients with type I and
type II C1-INH-HAE but do not necessarily arise as a consequence of
previous administration of C1-INH concentrate; furthermore,
C1-INH-Abs that occur in patients with C1-INH-HAE do not appear
to be inhibitory or neutralizing.15,16 Data from a large open-label
extension study suggest that pnfC1-INH treatment of patients
with C1-INH-HAE was not associated with the development of
inhibitory C1-INH-Abs.17 However, further research is needed to
conﬁrm these ﬁndings.
The current study was designed to assess whether use of
pnfC1-INH in patients with C1-INH-HAE type I or type II is associ-
ated with an increased incidence of C1-INH-Abs that inhibit C1-INH
function. An exploratory objective was to evaluate the efﬁcacy of
pnfC1-INH in individuals with and without C1-INH-Abs.Methods
Study Design
This prospective, international, multicenter, nonrandomized,
open-label study (NCT01467947) was conducted at 4 study centers
in Poland, Romania, Bulgaria, and Hungary between November 23,
2011, and October 17, 2014. Study procedures were conducted in
accordance with the International Conference on Harmonisation
Good Clinical Practice guidelines, and the protocol was approved by
a central independent ethics committee for each participatingActive
pnfC1-INH inf
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Figure 1. Study design. HAE, hereditary angioedema; pnfC1-INcenter. All participants or a legally acceptable representative pro-
vided written informed consent.
Patients with C1-INH-HAE were treated per routine medical
practice and followed up for 9months after the ﬁrst study-recorded
HAE attack treated with pnfC1-INH (Fig 1). In a previous phase 3
trial in which patients were tested for Ab status approximately
every 3 months,17 19 of 57 patients (33%) tested positive at least
once for antieC1-INH-Abs (all noninhibitory), including 8 who
tested positive at screening. Therefore, the current study design
with 4 sampling time points and 3-month intervals between
sampling time points was expected to provide an adequate dura-
tion of observation to characterize the dynamics of C1-INH-Ab
formation.
The study enrolled male and female participants 12 years or
older with a diagnosis of C1-INH-HAE type I or II and who were
assessed by the investigator as being likely to require treatment
with pnfC1-INH during the 9-month study period. Exclusion
criteria included the use of C1-INH products other than pnfC1-INH
within 30 days of the study or planned during the study, immu-
nization within 30 days of study entry, autoimmune conditions
requiring immunosuppressant therapy during the study, and pre-
vious participation in a study of pnfC1-INH for which C1-INH-Ab
results had been submitted to the US Food and Drug Administra-
tion. Concomitant therapy with any other approved or experi-
mental human or recombinant C1-INH was prohibited throughout
the study. The following concomitant therapies were prohibited
during the acute phase of treatment (from 24 hours before start of
attack until resolution of attack): any approved or experimental
drug that targeted the biological mechanisms of action of C1-INH;
fresh frozen plasma; attenuated androgens, tranexamic acid, or
aminocaproic acid (for individuals not previously treated); or
increased doses of these drugs (for individuals already receiving
such treatment).
Patients received 20 IU/kg of pnfC1-INH (Berinert) at the study
site for each HAE attack warranting such treatment. There was no
time limit between screening and the ﬁrst HAE attack. Once the
ﬁrst recorded study attack occurred, the patient was followed up
for the subsequent 9months. Any doses of pnfC1-INH given outside
the study site were not included in the study analysis.
Assessments
Clinical and demographic characteristics were recorded at
baseline. Each patient maintained a diary to record changes in
concomitant therapy, adverse events (AEs) occurring between of-
ﬁce visits, the time to onset of HAE symptom relief (TtRel) after
pnfC1-INH administration, and the time to complete resolution of
all HAE attack symptoms (TtRes). Patients were contacted by treatment period:
usion in case of HAE attack
Day 273
(Month 9)
Study Completion
Day 182
(Month 6)
Antibody testing Antibody testing
H, pasteurized, nanoﬁltered plasma-derived C1 inhibitor.
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pnfC1-INH to review the subject diary and to inquire about AEs,
concomitant medications, and resolution of HAE symptoms.
C1-INH-Abs
Blood samples (5 mL) for the assessment of C1-INH-Abs were
collected on day 1 (baseline; day of ﬁrst treated study attack) and at
3, 6, and 9 months and were analyzed by a central laboratory for
inhibitory C1-INH-Abs (iC1-INH-Abs) and noninhibitory C1-INH-
Abs (niC1-INH-Abs). Samples were stored between 20C
and 70C as citrate plasma. The assay for detecting antieC1-INH-
Abs was based on the principle of a direct binding enzyme-linked
immunosorbent assay (ELISA) (screening and conﬁrmatory assays,
described below).
AntieC1-INH-Ab screening assay
Puriﬁed pnfC1-INH was coated onto microplates and probed by
subject samples, and antieC1-INH-Abs were detected using a sec-
ond enzyme-conjugated Ab complex recognizing human IgM, IgG,
and IgA. Positivity for antieC1-INH-Abs was based on a titer of 1:50
or greater. The presence of speciﬁc C1-INH-Abs was conﬁrmed
using antieC1-INH isotyping assays, and titrations of samples were
assayed for quantiﬁcation. To minimize the probability of false-
negative results, the detection limit would allow the determina-
tion of false-positive results with a probability of approximately 5%.
This cutoff was determined by testing of samples from at least 100
healthy individuals.
AntieC1-INH isotyping assays (conﬁrmatory assay)
The presence of speciﬁc C1-INH-Abs was to be conﬁrmed in
antieC1-INH-Ab isotyping assays. In addition, titrations of the
samples were to be assayed for quantiﬁcation. The assay proced-
ures were similar to the screening assay. In contrast, for detection of
isotype M, G, and A, 3 different anti-human horseradish perox-
idaseelabeled conjugated polyclonal Abs were used. Serial sample
dilutions were analyzed, with the titer determined as the last
sample dilution before the cut-off.
Samples that tested above the cutoff by screening ELISA were
subjected to antieC1-INH-Ab inhibitory assay for assessing the
neutralizing capacity of the respective Abs. Equal volumes of
standard human plasma were to be mixed with the subject sample
and incubated at 37C for a standard period. The residual C1-INH
activity was to be measured and compared with control samples.
Safety
Physical examination and laboratory safety parameters (hema-
tology and blood chemistry; urinalysis) were performed on day 1
(baseline), month 3, and month 9 (or study completion). Vital signs
were evaluated on day 1 and at each HAE attack treatment visit. AEs
and changes in concomitant therapy were recorded throughout the
study in the patient diary. The investigator graded the intensity of
each AE as follows: mild (symptoms were easily tolerated and did
not interfere with daily activities), moderate (symptoms caused
enough discomfort to cause some interference with daily activ-
ities), and severe (symptoms were incapacitating, with inability to
work or perform usual activities).
Statistical Analysis
Determination of sample size
On the basis of previous clinical experience,17 the prevalence of
patients being Ab positive (Abþ) at time of enrollment in the study
was expected to be approximately 15%. The percentage of patients
who were Ab negative at study start and Abþ at study end was also
expected to be 15%, resulting in an expected total percentage of
Abþ patients of 30% at the end of study. A limit of 20%was set as therelevant upper threshold for the incidence proportion of patients
with iC1-INH-Abs. With a conservative assumption of 4.5% of pa-
tients having iC1-INH-Abs, then a sample size of at least 40 patients
was determined to provide approximately 80% power for an inci-
dence less than 20%, with a 1-sided a of 2.5%.
General considerations
Summary statistics (mean [SD], median [range]) were presented
for continuous variables, and 2-sided 95% conﬁdence intervals (CIs)
were presented when appropriate. In addition, summary statistics
were presented for categorical variables (group frequencies and
percentages). All data were analyzed using SAS statistical software,
version 9.2 (SAS Institute Inc).
Study end points
The primary end point was iC1-INH-Abs. The number and per-
centage of patients categorized as positive or negative for iC1-INH-
Abs for each visit and the incidence of patients with at least 1
positive postbaseline result were summarized. The percentage and
incidence proportion of patients with at least 1 positive postbase-
line result were to be presented with the corresponding 95% CIs
based on the Wilson score. The secondary end point was C1-INH-
Abs (inhibitory or noninhibitory). The number and percentage of
patients categorized as positive or negative for any C1-INH Abs,
whether inhibitory or noninhibitory, for each visit and the inci-
dence of patients with at least 1 positive postbaseline result were
determined by visit and overall.
Efﬁcacy variables
The TtRel and TtRes per attack and per patient were summa-
rized descriptively overall and for patients with and without C1-
INH-Abs at any point during the study.
Safety variables
The number and percentage of patients experiencing treatment-
emergent AEs and discontinuations attributable to AEs were sum-
marized. Treatment-emergent AEs were summarized by relation-
ship to studymedication and by severity. Serious AEswere included
in overall tallies and also described separately. Laboratory param-
eters and vital signs were summarized by visit. Abnormal physical
examination results were recorded as AEs if noted at a visit after the
ﬁrst attack (pnfC1-INH administration).
Results
Study Participants
Sixty patients were screened and met the study inclusion/
exclusion criteria; of these, 14 did not experience an HAE attack
requiring pnfC1-INH treatment before the study ended. Because
they did not receive the study drug, these 14 individuals were
excluded from all analyses. The remaining 46 patients had at least 1
pnfC1-INHetreated attack during the study and comprised the full
analysis population and the safety set. All 46 patients completed
the entire 9 months of study participation.
Patients were predominantly female (69.6%) and white (100.0%)
and ranged in age from 14 to 78 years (mean [SD], 38.9 [14.4] years).
Most patients had C1-INH-HAE type I (82.6%). Mean (SD) body
mass index (calculated as the weight in kilograms divided by the
square of height in meters) was 25.0 (4.8). For all patients, themean
(SD) time since HAE diagnosis was 11.0 (7.6) years. The mean
number of prior HAE attacks in the 6 months before the start of the
active treatment period was 4.3 attacks, with the greatest per-
centage of patients (41.3%) reporting 3 attacks in the last 6 months.
The most commonly reported HAE attacks during the 6 months
before study entry were peripheral (87.0% of patients) and
abdominal (60.9% of patients), with laryngeal and facial attacks
reported less frequently (10.9% and 23.9% of patients, respectively).
Table 1
Results of C1-INH-Ab Testing
Test Patients, n (%) (N ¼ 46)
iC1-INH-Absa
Negative at all study time points 46 (100)
Positive at 1 time point during the study 0
niC1-INH-Abs
Negative at all study time points 33 (71.7)
Positive at 1 time point during the study 13 (28.3)
Abbreviations: C1-INH-Ab, C1 inhibitor antibody; iC1-INH-Abs, inhibitory C1-INH
antibodies; niC1-INH-Abs, noninhibitory C1-INH antibodies.
aPrimary end point.
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A total of 221 HAE attacks in 46 patients were treated with
pnfC1-INH at the study site. An additional 101 HAE attacks were
treated outside the study site with a variety of medications,
including 22 infusions of pnfC1-INH administered to 8 patients;
data from these attacks are not reported here. Most patients were
treated for 1 (30.4% of patients) or 2 (21.7%) attacks at the study site,
whereas 23.9% of patients were treated for more than 6 HAE attacks
(range, 7e21 attacks). The most common anatomical locations of
attacks were peripheral and abdominal attacks, reported by 56.5%
and 52.2% of participants, respectively. Most patients (87.0%) re-
ported at least 1 moderate intensity attack, and 58.7% of patients
reported at least 1 severe attack. Most attacks (n ¼ 133 [60.2%])
were moderate in severity.C1-INH Antibodies
None of the 46 patients tested positive for iC1-INH-Abs at any
time during the study (95% CI for Wilson score for incidence,
0.000e0.077) (Table 1). The upper limit of the CI was less than 20%,
and the incidence of iC1-INH-Abs in patients with HAE treated with
pnfC1-INH can be assumed to be less than 20%.
Thirteen patients (28.3%) tested positive for niC1-INH-Abs at
least once at any time during the study (at baseline or after base-
line). Thirty-three patients (71.7%) did not test positive for
niC1-INH-Abs at any time point during the study. The percentage of
participants who tested positive for niC1-INH-Abs at any one study
visit, including baseline, ranged from 13.3% to 19.6% of participants
(Table 2). Most positive titers (20 [70.0%] of 29) were 1:50, whereas
a few titers were between 1:150 and 1:300 (Table 2).Table 2
Antibody Titers by Study Visit for Patients With at Least 1 Positive niC1-INH-Ab
Result by Baseline Ab Status
Patient Antibody titers by study visit (total study N ¼ 46)
Day 1 (baseline) Month 3 Month 6 Month 9
No detectable niC1-INH-Abs at baseline
A . . 1:50 1:50
B . 1:50 . .
C . . . 1:50
D . 1:50 . .
Detectable niC1-INH-Abs at Baseline
E 1:50 1:50 . .
F 1:50 . . .
G 1:150 1:150 1:150 1:150
H 1:50 1:50 1:50 1:50
I 1:50 . 1:50 1:50
J 1:50 1:150 1:150 1:50
K 1:50 . . .
L 1:50 . . .
M 1:50 1:150 1:300 1:200
No. (%) of patients with Abs 9 (19.6) 7 (15.2) 6 (13.3) 7 (15.2)
Abbreviations: Ab, antibody; niC1-INH-Abs, noninhibitory C1 inhibitor antibodies.Ten patients (21.7%) had at least 1 detectable result for
niC1-INH-Abs after baseline, for an incidence of 0.087 (95% CI for
Wilson score for incidence, 0.034e0.203). Of these patients, 6 had
detectable Abs on day 1 (baseline), whereas 4 had at least 1
detectable result for Abs after baseline with none detected at day 1
(baseline).
Among the 4 patients who were antibody negative at baseline
and had positive niC1-INH-Ab titers at 1 or more subsequent study
visits, the number of pnfC1-INH infusions during the study ranged
from 1 to 3 (Table 2). Three patients had positive niC1-INH-Abs
titers at baseline but nondetectable titers at all other study visits;
these patients had 1, 5, and 9 pnfC1-INH infusions, respectively,
during the study.
Efﬁcacy
The mean TtRel per attack and TtRel per patient were similar for
the 13 patients (35 attacks) who tested positive for niC1-INH-Abs
and the 33 patients (186 attacks) who had no C1-INH-Abs at any
assessment during the study, including baseline (Table 3). The
mean TtRes per attack was approximately 10 hours shorter for the
13 patients (35 attacks) who tested positive at least once for
niC1-INH-Abs compared with the mean TtRes for the 33 patients
(186 attacks) who had no detectable C1-INH-Abs at any assessment
during the study (Table 3). The mean TtRes per patient was similar
between the 2 groups.
Safety
A total of 52 AEs were reported in 15 patients (32.6%) who
received 1 dose or more of pnfC1-INH at the study site. None of the
AEs were considered related to pnfC1-INH or its administration.
The most commonly reported AEs were headache (26 events re-
ported in 6 patients), hypotension (3 events reported in 3 patients),
upper respiratory tract infection (3 events reported in 2 patients),
and oropharyngeal pain (2 events reported in 2 patients); all other
AEs were reported in 1 patient each. Two of the 3 AEs of hypo-
tension occurred during abdominal HAE attacks, and 1 occurred
during a peripheral HAE attack. Most AEs were of moderate or
severe intensity.
A total of 2 serious AEs (SAEs), spontaneous abortion and an
acute abdominal HAE attack of severe intensity, occurred in a total
of 2 patients (4.3%). Both of these SAEs were considered unrelated
to pnfC1-INH or the study procedure. The patient who experienced
the spontaneous abortion received no further pnfC1-INH treatment
(per protocol guidelines in the event of pregnancy occurring during
the study) but continued with all other study procedures. No
thromboembolic AEs or deaths were reported during the study.
No clinically signiﬁcant treatment-emergent changes were
noted for hematology, blood chemistry, or urinalysis assessments.
No treatment-emergent changes in vital signs were consideredTable 3
Association Between niC1-INH-Abs and Efﬁcacy Outcomes
With niC1-INH-Absa Without niC1-INH-Absb
No. of patients 13 33
No. of attacks 35 186
Time to onset of relief, mean (SD) [95% CI], h
Per attack 1.51 (4.07) [0.11e2.91] 1.40 (0.80) [1.29e1.52]
Per participant 1.17 (1.43) [0.31e2.04] 1.31 (0.60) [1.10e1.52]
Time to symptom resolution, mean (SD) [95% CI], h
Per attack 22.86 (21.06) [15.62e30.09] 33.59 (58.47) [25.13e42.05]
Per participant 31.02 (24.08) [16.46e45.57] 29.59 (18.59) [23.00e36.18]
Abbreviations: CI, conﬁdence interval; niC1-INH-Abs, noninhibitory C1 inhibitor
antibodies.
aAt any study visit.
bAt all study visits.
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reported for 3 patients in whom decreased blood pressures were
transient and temporally associated with HAE attacks. All clinically
signiﬁcant physical examination ﬁndings were consistent with
signs or symptoms of HAE attacks and were limited to edema, pain,
or tenderness at the sites of HAE attack.Discussion
The presence of iC1-INH-Abs has been described in the context
of acquired angioedema in which circulating auto-Abs cause the
inactivation and catabolism of C1-INH.11e13 Administration of
exogenous proteins has the potential to induce formation of
inhibitory and noninhibitory Abs,9,10 and this phenomenon
continues to be a subject of interest in HAE patients treated with
C1-INH products. In the current study, pnfC1-INH did not induce
formation of iC1-INH-Abs in patients with C1-INH-HAE. This
observation is consistent with the ﬁndings of the International
Multicentre Prospective Angioedema C1-INH Trial (IMPACT) 2
study of pnfC1-INH in patients with C1-INH-HAE.17 In that pro-
spective study conducted at 15 centers in North America, 57 pa-
tients with C1-INH-HAE were administered pnfC1-INH for a
median study duration of 24 months for treatment of HAE attacks.
Samples were drawn every 3 months to test for C1-INH-Abs. No
iC1-INH-Abs were detected in any patient in the IMPACT 2 study. In
addition, long-term treatment with pnfC1-INH was not associated
with signiﬁcant changes in antieC1-INH IgG, IgA, or IgM titers or
with evidence of abnormally high titers characteristic of patients
with acquired C1-INH deﬁciency.18 A lack of inhibitory antibody
development has also been noted in association with C1-INH
products other than pnfC1-INH, including both human plasma-
derived19e21 and recombinant human C1-INH (rhC1-INH).9,22
In the current study, 13 patients (28.2%) had detectable levels of
niC1-INH-Abs at 1 ormore assessments during the study, including9
patients (19.6%) who had detectable niC1-INH-Abs at baseline.
Similarly, in the IMPACT 2 study, 33% of patients were noted to have
detectable niC1-INH-Abs at least once.17 The presence of niC1-INH-
Abs in the current study did not appear to inﬂuence the efﬁcacy of
pnfC1-INH as assessed by time to onset of symptom relief or time
to complete resolution of HAE symptoms, as evaluated per attack
or per patient. Regardless of the presence of niC1-INH-Abs, onset of
relief typically occurred within approximately 1.5 hours, and com-
plete resolution of HAE symptoms was generally achieved within
35 hours. These results are consistent with those reported in
the IMPACT 2 study, which found that median times to onset of
symptom relief and complete resolution of HAE symptoms were
comparable when analyzed according to the presence or absence of
niC1-INH-Abs.23
Data from the current study add to an accumulating body of
evidence suggesting that C1-INH-Abs are detectable in approxi-
mately one-third of C1-INH-HAE patients treated with C1-INH.
Findings suggest that the antibodies are not inhibitory, are often
transient, and do not lessen the clinical response to C1-INH
administration. A prospective study of 95 patients with type I or
type II C1-INH-HAE followed up for a 4-year period found that
C1-INH-Abs were detected at a similar frequency between patients
treated with C1-INH concentrate and treatment-naive patients.15 In
C1-INH concentrate-naive patients, a strong positive correlation
was observed between titers of IgM type C1-INH-Abs and disease
severity, with 5 of 6 patients with frequently occurring high-titer
IgM C1-INH-Abs having disease of the highest severity. IgM type
C1-INH-Ab titers were also strongly correlated with attack fre-
quency. The authors suggested that this correlation is likely
attributable to high-titer IgM-type C1-INH-Abs developing as a
consequence of activation of the classic complement pathway and
other plasma enzyme systems during acute attacks. A subsequentstudy by some of the same authors, which included 130 patients
with type I or type II C1-INH-HAE followed up for up to 11 years,
conﬁrmed that IgM C1-INH-Abs are commonly observed in HAE,
with 31% of patients followed up for 9 to 11 years having IgM
C1-INH-Abs in more than 3 serum samples.15 Presence of
IgMC1-INH-Abs was not related to previous C1-INH concentrate
treatment.
An integrated analysis of 5 clinical trials (2 of which were open-
label extension studies) evaluated the immunogenicity of rhC1-INH
in 155 symptomatic HAE patients who received a total of 424 ad-
ministrations of rhC1-INH.9 The proportions of antieC1-INH-Ab
screening test results that were above the cutoff level were simi-
larly low for preexposure (1.5%) and postexposure (1.3%) plasma
samples. No neutralizing antibodies were detected, and there was
no correlation between antibody ﬁndings and efﬁcacy or AEs
associated with rhC1-INH treatment. In a recent open-label
extension study of rhC1-INH, no neutralizing antibodies were
found after repeated treatment.22 Five patients had antierhC1-INH
antibodies of the IgG isotype, but these were not apparently clini-
cally relevant because similar efﬁcacy was observed for these pa-
tients in the presence and absence of positive antibody results (ie,
during attacks when antibody levels were elevated vs unelevated).
The antigenic potential of plasma-sourced therapeutic agents
appears to differ between HAE and hemophilia. Inhibitory anti-
bodies to factor VIII (FVIII) are a clinically relevant phenomenon in
approximately 25% of patients with severe hemophilia24 but have
not been observed in HAE with C1-INH therapy. Although the
reasons for this phenomenon are not yet clear, certain theoretical
explanations can be entertained. In some patients with hemophilia,
there is a severe deﬁciency mutation within the FVIII gene.24 As a
result, there is a complete absence of protein production, and the
exogenous protein may present as a neoantigen. In contrast, pa-
tients with C1-INH-HAE have at least some intrinsic C1-INH, and
the protein is familiar to the immune system.25 Furthermore, dif-
ferences in immunogenicity to C1-INH compared with FVIII may be
related to the fact that inhibitory Abs react with the reactive center
loop of the C1-INH, which is a very conservative region, whereas
the C1 and C2 domains in FVIII evolutionally appeared later.26,27 It is
reported that hemophilia patients with missense mutations in the
C1 and C2 domains of FVIII have a 3-fold higher risk of developing
FVIII inhibitors than patients with missense mutations in other
domains.28 Finally, most patients with HAE are exposed to exoge-
nous C1-INH on a sporadic and sometimes infrequent basis,
whereas patients with hemophilia A are more likely to receive
regular and more frequent administration of FVIII.
Interpretation of the study results is limited by the absence of
conﬁrmed pnfC1-INHenaive patients at baseline and the lack of a
control group. All study participants were white; the racial distri-
bution likely reﬂects the predominant demographics of the Eastern
European countries in which this study was conducted. The study
duration of 9 months could be considered a possible limitation,
given the possibility that the frequency and nature of antibody
development might differ with longer treatment exposure.
Results of this open-label, uncontrolled study suggest that
administration of a highly puriﬁed human plasma-derived C1-INH
is not associated with the development of inhibitory antibodies in
C1-INHedeﬁcient patients (type I or type II C1-INH-HAE), likely
reﬂects immunotolerance to the human C1-INH protein.
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